The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models

BACKGROUND: The Ras/RAF/MEK/ERK pathway is frequently deregulated in cancer and a number of inhibitors that target this pathway are currently in clinical development. It is likely that clinical testing of these agents will be in combination with standard therapies to harness the apoptotic potential...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Holt, S V, Logié, A, Odedra, R, Heier, A, Heaton, S P, Alferez, D, Davies, B R, Wilkinson, R W, Smith, P D
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2012
Témata:
Translational Therapeutics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3305954/
https://ncbi.nlm.nih.gov/pubmed/22343622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.8
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky